The fight against AIDS has reached a "watershed," said Marilynn Marchione and Michael Casey in the San Francisco Examiner. Researchers announced in Bangkok Thursday that an experimental vaccine had cut the risk of infection with HIV—the virus that causes AIDS—by 31 percent in a trial of more than 16,000 volunteers. This was the largest AIDS vaccine trial yet, and the first time a drug had prevented infection with the AIDS virus.
There's no question this is significant, said Donald G. McNeil Jr. in The New York Times, but this new HIV vaccine still "protected too few people to be declared an unqualified success." And it left scientists "delighted but puzzled"—the RV 144 vaccine was actually a combination of two genetically engineered vaccines, but neither of them had worked before in humans.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
